Silence Therapeutics PLC (NASDAQ:SLN) — Market Cap & Net Worth
Market Cap & Net Worth: Silence Therapeutics PLC (SLN)
Silence Therapeutics PLC (NASDAQ:SLN) has a market capitalization of $326.86 Million ($326.86 Million) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #14549 globally and #3402 in its home market, demonstrating a 13.45% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Silence Therapeutics PLC's stock price $7.00 by its total outstanding shares 47233949 (47.23 Million). Review Silence Therapeutics PLC balance sheet liabilities to assess the company's total debt and financial obligations.
Silence Therapeutics PLC Market Cap History: 2020 to 2026
Silence Therapeutics PLC's market capitalization history from 2020 to 2026. Data shows change from $1.04 Billion to $330.64 Million (-16.27% CAGR).
Index Memberships
Silence Therapeutics PLC is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.44 Trillion | 0.01% | #386 of 976 |
|
NASDAQ Composite
IXIC
|
$41.39 Trillion | 0.00% | #1409 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.02% | #204 of 263 |
Weight: Silence Therapeutics PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Silence Therapeutics PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Silence Therapeutics PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
7.51x
Silence Therapeutics PLC's market cap is 7.51 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.04 Billion | $5.48 Million | -$32.55 Million | 189.66x | N/A |
| 2021 | $1.13 Billion | $12.41 Million | -$39.41 Million | 90.89x | N/A |
| 2022 | $720.32 Million | $21.66 Million | -$50.33 Million | 33.26x | N/A |
| 2023 | $820.45 Million | $25.38 Million | -$43.27 Million | 32.33x | N/A |
| 2024 | $324.97 Million | $43.26 Million | -$45.31 Million | 7.51x | N/A |
Competitor Companies of SLN by Market Capitalization
Companies near Silence Therapeutics PLC in the global market cap rankings as of June 17, 2026.
Key companies related to Silence Therapeutics PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #443 globally with a market cap of $63.36 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $450.46 |
| #443 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.36 Billion | $614.98 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €259.20 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €761.20 |
Silence Therapeutics PLC Historical Marketcap From 2020 to 2026
Between 2020 and today, Silence Therapeutics PLC's market cap moved from $1.04 Billion to $ 330.64 Million, with a yearly change of -16.27%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $330.64 Million | +15.13% |
| 2025 | $287.18 Million | -11.63% |
| 2024 | $324.97 Million | -60.39% |
| 2023 | $820.45 Million | +13.90% |
| 2022 | $720.32 Million | -36.17% |
| 2021 | $1.13 Billion | +8.59% |
| 2020 | $1.04 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of Silence Therapeutics PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $326.86 Million USD |
| MoneyControl | $326.86 Million USD |
| MarketWatch | $326.86 Million USD |
| marketcap.company | $326.86 Million USD |
| Reuters | $326.86 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Silence Therapeutics PLC
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated … Read more